CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
Enzalutamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02091960
NCT02091960Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Astellas Pharma Global Development, Inc.·interventional·Posted Mar 19, 2014·Updated Apr 4, 2025

In Brief

A Phase 2 clinical trial evaluating Enzalutamide and Trastuzumab for HER2 Amplified and 2 related conditions. Completed, enrolled 103 participants across 39 sites in 6 countries.

Detailed Summary

The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
CountriesBelgium, Canada, Italy, Spain, United Kingdom, United States
CollaboratorsMedivation LLC, a wholly owned subsidiary of Pfizer Inc.

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 19, 2014
Enrollment StartSep 5, 2014
Primary CompletionFeb 28, 2017
Study CompletionJan 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.3 years ago

Interventions

Enzalutamidedrug

Capsules for oral administration

Trastuzumabdrug

Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country